RNA epigenetic modifications have uncovered as not only an intermediary structure between DNA and protein or an effector ...

TransCode Therapeutics has developed an iron oxide nanoparticle–based therapeutic RNA delivery system that maximizes targeted tumor uptake while minimizing clearance. With a lead candidate in ...

Over the past decade, advances in the RNA field have revealed new opportunities for the development of therapeutics, in particular those based on RNA interference (RNAi). Our two interviewees this ...

While still early days, there is a lot of promise here too. Probably the most attractive aspect of RNA therapeutics is that it forms essentially the best form of immunotherapy, by working directly ...

RNA therapeutics market is expanding, driven by advancements in gene therapy, personalized medicine, and RNA-based drug delivery, along with rising research in mRNA vaccines, antisense ...

RNA therapeutics have existed since the late 90s but have only come into focus in the last few years. This renewed interest has largely been attributed to the success of messenger RNA (mRNA) vaccines ...

WALTHAM, Mass.--(BUSINESS WIRE)--Arrakis Therapeutics, a biopharmaceutical company pioneering the discovery of a new class of small molecule medicines that directly target RNA, today announced ...

SMi’s 11 th annual RNA Therapeutics conference, taking place on 19 th – 20 th February in London, will bring together industry experts from leading RNA therapeutics companies to discuss the ...

BOSTON, March 25, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), ("TransCode" or the "Company"), the RNA oncology company committed to more effectively treating cancer using RNA ...